AstraZeneca, Daiichi revise approval plans for Enhertu successor
Summary: Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and instead are aiming for a narrower approval.
Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS
Summary: Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in people living with the nerve-destroying disorder.
Bayer drops Huntington’s gene therapy to focus on ‘most promising assets’
Summary: Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma giant canned its clinical-stage gene therapy for the disease.
Insilico’s AI-designed med tied to respiratory health improvements in midstage lung disease trial
Summary: Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated improvements in a respiratory health measure for patients with idiopathic pulmonary fibrosis (IPF).
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
Summary: DNA-testing company 23andMe ME 2.17%increase; green up pointing triangle said on Monday that it was firing roughly 40% of its workforce, more than 200 people, as Chief Executive Anne Wojcicki seeks to stabilize her money-losing business.
